Skip Page Header

Home > Opioid antagonists for smoking cessation.

David, Sean P and Lancaster, Tim and Stead, Lindsay F and Evins, A Eden and Prochaska, Judith J [The Cochrane Library] . (2013) Opioid antagonists for smoking cessation. London: John Wiley & Sons, Ltd. Cochrane Database of Systematic Reviews (6) Art. No.: CD003086. DOI: 10.1002/14651858.CD003086.pub3.


Opioid antagonists are a type of drug which blunts the effects of narcotics such as heroin and morphine, and might help reduce nicotine addiction by blocking some of the rewarding effects of smoking. Our review identified eight trials of naltrexone, a long-acting opioid antagonist. The trials included over 1200 smokers. Half the trials gave everyone nicotine replacement therapy and tested whether naltrexone had any additional benefit. Compared to a placebo, naltrexone did not increase the proportion of people who had stopped smoking, at the end of treatment, or at six months or more after treatment, either on its own or added to NRT. The available evidence does not suggest that opioid antagonists such as naltrexone assist smoking cessation.

Item Type
Evidence resource
Publication Type
Drug Type
Intervention Type
AOD disorder drug therapy
John Wiley & Sons, Ltd
Place of Publication
Accession Number
HRB (Not in collection)

Repository Staff Only: item control page